Which GLP-1 Telehealth Programs Carry All Four Brand-Name Drugs? (2026)

If you want one program that can move you between Wegovy, Ozempic, Mounjaro, and Zepbound without switching providers, this is the list: ordered by how many of the four brand-name drugs each program verifiably names on its own site. A breadth comparison, not a price ranking.

By RangeYourselfUpdated July 16, 20269 programs compared

Mochi Health and Wellorithm verifiably name all four FDA-approved brand-name GLP-1s (Wegovy, Ozempic, Mounjaro, Zepbound) on their own sites. Naming a drug is not publishing a price for it: the per-drug basis sits in each row, and ranked pricing lives on the four per-drug pages linked below.

Wegovy and Ozempic (semaglutide) are made by Novo Nordisk; Mounjaro and Zepbound (tirzepatide) by Eli Lilly. All four are FDA-approved finished-drug products; compounded semaglutide and tirzepatide are different, cheaper, non-FDA-approved preparations. This page orders programs by how many of the four brands they carry, then alphabetically. It ranks nothing on price.

Programs by brand-name breadth

9 programs that name at least one brand-name GLP-1 on their own site, ordered by how many of the four they name; per-drug cells show each program's own published basis, never a ranking.
Program	Wegovy	Ozempic	Mounjaro	Zepbound	Verified
Mochi Health 4 of 4 brands named See program →	insurance-billed	insurance-billed	insurance-billed	insurance-billed	2026-07-27	See program →
Wellorithm 4 of 4 brands named See program →	named, no price	named, no price	named, no price	named, no price	2026-07-25	See program →
Found 3 of 4 brands named See program →	$650/mo, fee basis unclear	$1100/mo, fee basis unclear	not named	$650/mo, fee basis unclear	2026-07-27	See program →
Ro 3 of 4 brands named See program →	$149-$299/mo	$900-$1100/mo	not named	$299-$449/mo	2026-08-20	See program →
Sesame Care 3 of 4 brands named See program →	$149-$299/mo	$349-$499/mo	not named	$299-$698/mo	2026-07-25	See program →
WeightWatchers 3 of 4 brands named See program →	$149/mo	$149/mo	not named	$299/mo	2026-07-16	See program →
Luvo Health 2 of 4 brands named See program →	not named	$1299 per 4 wks	not named	$1399 per 4 wks	2026-08-08	See program →
ShedRx 2 of 4 brands named See program →	$499/mo	not named	not named	$349/mo	2026-07-27	See program →
Sprout Health 2 of 4 brands named See program →	$1799/mo	not named	not named	$1999/mo	2026-08-21	See program →

About compounded GLP-1 medicationsCompounded semaglutide and tirzepatide are not FDA-approved finished products. They are prepared by state-licensed 503A pharmacies or 503B outsourcing facilities and are not individually reviewed by the FDA for safety, effectiveness, or quality. Compounders describe these preparations as using the same active ingredient as the approved medicines; the FDA has warned that some compounded products use salt forms, semaglutide sodium or semaglutide acetate, that it considers different active ingredients from the approved drug, and has issued warning letters over marketing that presents a compounded preparation as interchangeable with an approved one. The FDA declared the semaglutide shortage resolved on February 21, 2025 and the tirzepatide shortage resolved in December 2024, so the shortage-era pathway for broad compounding of these drugs has ended. Compounding now proceeds under the ordinary rules: a 503A pharmacy compounding for an individual patient on a prescription, or a 503B outsourcing facility, which compounds in bulk under CGMP and FDA registration rather than per patient. Those rules generally do not cover a product that is “essentially a copy” of an approved drug unless a prescriber documents a change that makes a significant difference for an individual patient. Talk to a clinician about contraindications including personal or family history of medullary thyroid carcinoma or MEN 2. RangeYourself does not provide medical advice, does not guarantee a prescription, and does not guarantee weight-loss results.

RangeYourself is reader-supported. We may earn a commission when you click on certain links, at no extra cost to you. Editorial recommendations are made independently. Each per-drug basis carries its own verification date; the oldest on this page is July 16, 2026.

Common questions

Which telehealth programs carry all four brand-name GLP-1s?

Mochi Health and Wellorithm are the programs in our registry that verifiably name Wegovy, Ozempic, Mounjaro, and Zepbound on their own sites. Naming a drug is not the same as publishing a price for it: see each row's per-drug basis, and the per-drug pages linked below for ranked pricing where it exists.

Why does carrying more brands matter?

Dose tolerance, supply, and insurance formularies change. A program that carries several brand-name GLP-1s can move you between them on the same account and with the same prescriber, instead of requiring a new program. That is a convenience and continuity consideration, not a quality or safety claim.

Is this a price ranking?

No. Rows are ordered by how many of the four drugs a program names, then alphabetically. Each row shows its own published basis per drug (cash, insurance-billed, or named without a price). Ranked per-drug pricing lives on the Wegovy, Ozempic, Mounjaro, and Zepbound pages.

Alert me when this gets cheaper

These prices move. Get one email when we publish a verified price drop, the programs on this list included. No spam. Unsubscribe any time.

Programs by brand-name breadth

Common questions

Alert me when this gets cheaper

Ranked pricing per drug